Pharmaxis Ltd (ASX:PXS) is an Australian pharmaceutical research company with expertise in developing drugs for inflammatory and fibrotic diseases and focussed on myelofibrosis.
The company expects to announce receipt of milestone payments and the start of sales from its Bronchitol treatment in the near-term.
